K-numberK260076
Device nameSAM 3.0 Multi-Hour Continuous Ultrasound Device
ApplicantZetrOZ Systems, LLC
Product codePFW
Device classClass II
Decision dateApr 28, 2026
DecisionSubstantially Equivalent
Regulation890.5300
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The SAM 3.0 is a home-use ultrasound device that applies continuous ultrasonic energy at 3 MHz to generate deep heat in body tissues. It is intended to treat selected musculoskeletal conditions including pain relief, muscle spasms, joint contractures, and circulatory improvements, with specific applications to knee osteoarthritis, chronic myofascial pain, and shoulder/elbow/ankle tendinopathy.

Technological characteristics

The SAM 3.0 is nearly identical to its predicate (SAM 2.0) with the same acoustic parameters: 3 MHz frequency, 0.65W single applicator or 1.3W dual applicator output, 4-hour maximum treatment duration, and 18,720 Joules maximum energy delivery. The primary differences are: added software control functions replacing solid-state IC chips, new LED indicators showing applicator warming and therapeutic heating status, and a slightly larger controller (2.34 cm vs 1.88 cm thickness) to accommodate an extended-capacity lithium battery.

Test standards cited

IEC 60601-1-11 (2015) AMD 1 2020 for home healthcare environments; IEC 60601-1 ed. 3.2 (2020) for general safety and essential performance; IEC 60601-1-2 ed 4.1 (2020) for electromagnetic disturbances. Software testing was performed to demonstrate functional equivalency with the addition of control mechanisms and LED display functionality.

Substantial equivalence argument

The SAM 3.0 is substantially equivalent to the SAM 2.0 predicate because both devices share identical intended use, indications, therapeutic parameters (frequency, power, duration, energy), physical dimensions (applicators and treatment heads), acoustic characteristics, and safety profiles. The SAM 3.0's added software controls and battery capacity represent minor design enhancements that do not alter the fundamental therapeutic mechanism or performance. The predicate's clinical efficacy from prior systematic literature review applies equally to the SAM 3.0.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →